CYAN · XBRL financial data

Cyanotech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CYAN's year ends in late March)

In thousands of dollars	Q3 FY23Dec 31, 2022	Q4 FY23Mar 31, 2023	Q1 FY23Jun 30, 2023	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025
Revenue from contracts with customers	5,891	5,392*	5,146	6,373	5,582	5,970*	5,898	5,845	6,172	6,300*	5,820	6,976
Cost of goods and services sold	4,127	4,005*	3,614	4,285	3,933	5,295*	4,422	4,366	3,993	4,558*	4,047	4,583
Gross profit	1,764	1,387*	1,532	2,088	1,649	675*	1,476	1,479	2,179	1,742*	1,773	2,393
Research and development	106	214*	191	175	163	159*	84	137	127	101*	74	78
General and administrative	1,021	1,028*	1,274	1,160	947	1,083*	1,268	1,244	1,012	873*	1,300	996
Total operating expenses	2,168	2,641*	2,741	2,720	2,497	2,578*	2,517	2,454	2,229	2,184*	2,526	2,203
Operating income (loss)	(404)	(1,254)*	(1,209)	(632)	(848)	(1,903)*	(1,041)	(975)	(50)	(442)*	(753)	190
Interest expense	186	169*	160	163	172	173*	161	175	174	177*	173	189
Income tax expense (benefit)	8	7*	0	2	0	5*	0	0	0	8*	0	0
Net income (loss)	(598)	(1,430)*	(1,369)	(797)	(1,020)	(2,081)*	(1,202)	(1,150)	(224)	(627)*	(926)	1
Earnings per share, basic USD per share	(0.10)	(0.23)*	(0.22)	(0.13)	(0.16)	—	(0.17)	(0.16)	(0.03)	(0.09)*	(0.13)	0.00
Earnings per share, diluted USD per share	(0.10)	(0.23)*	(0.22)	(0.13)	(0.16)	—	(0.17)	(0.16)	—	—	—	0.00
Weighted average shares, basic thousands of shares	6,272	6,272*	6,290	6,366	6,554	—	6,948	7,004	7,156	7,177*	7,211	7,293
Weighted average shares, diluted thousands of shares	6,272	6,272*	6,290	6,366	6,554	—	6,948	7,004	—	—	—	7,293

Balance sheet

CSV

Fiscal quarters (CYAN's year ends in late March)

In thousands of dollars	Q3 FY23Dec 31, 2022	Q4 FY23Mar 31, 2023	Q1 FY23Jun 30, 2023	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025
Cash and cash equivalents	513	974	648	1,236	661	707	720	780	359	257	383	649
Accounts receivable	2,156	1,331	1,794	1,430	2,036	2,102	2,137	1,592	1,908	1,953	1,560	2,354
Inventory	11,574	10,707	10,506	9,591	9,124	7,313	6,961	7,185	7,751	7,788	8,110	8,378
Prepaid and other current assets	284	484	378	428	464	469	551	568	533	547	470	550
Total current assets	14,527	13,496	13,326	12,685	12,285	10,591	10,369	10,125	10,551	10,545	10,523	11,931
Property and equipment, net	11,693	11,366	11,065	10,775	10,434	10,109	9,783	9,505	9,256	8,927	8,590	8,353
Right-of-use asset	3,463	4,776	4,656	4,534	4,409	4,284	4,156	4,161	4,032	3,902	3,769	3,632
Total assets	29,772	29,728	29,132	28,082	27,254	25,112	24,432	23,913	23,956	23,490	22,995	24,027
Accounts payable	1,031	1,021	1,721	1,392	1,389	1,439	2,311	2,132	2,151	2,217	2,234	2,971
Accrued liabilities	988	1,101	821	897	753	757	587	619	593	715	740	920
Current portion of long-term debt	2,311	5,409	5,833	5,737	5,809	5,630	6,450	6,019	—	2,886	—	—
Total current liabilities	4,670	8,103	8,946	8,659	8,538	8,554	10,162	9,575	9,949	10,243	10,778	11,892
Long-term debt	4,166	1,000	1,000	1,000	1,000	1,000	0	1,000	1,000	1,000	1,000	1,000
Lease liability, non-current	3,203	4,275	4,146	4,016	3,883	3,744	3,610	3,646	3,507	3,363	3,217	3,070
Total liabilities	12,039	13,381	14,092	13,675	13,421	13,298	13,772	14,221	14,456	14,606	14,995	15,962
Accumulated deficit	(16,204)	(17,634)	(19,003)	(19,800)	(20,820)	(22,901)	(24,103)	(25,253)	(25,477)	(26,104)	(27,030)	(27,029)
Total stockholders' equity	17,733	16,347	15,040	14,407	13,833	11,814	10,660	9,692	9,500	8,884	8,000	8,065
Total liabilities and equity	29,772	29,728	29,132	28,082	27,254	25,112	24,432	23,913	23,956	23,490	22,995	24,027
Common shares outstanding (cover page) thousands of shares	6,272	6,291	6,308	6,487	6,887	6,948	6,960	7,156	7,156	7,232	7,242	7,392

Cash flows

CSV

Fiscal quarters (CYAN's year ends in late March)

In thousands of dollars	Q3 FY23Dec 31, 2022	Q4 FY23Mar 31, 2023	Q1 FY23Jun 30, 2023	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025
Net income (loss)	(598)	(1,430)*	(1,369)	(797)	(1,020)	(2,081)*	(1,202)	(1,150)	(224)	(627)*	(926)	1
Stock-based compensation	45*	44*	47	175*	54*	83*	48	146*	33*	20*	49	25*
Depreciation and amortization	409	412*	407	404	395	383*	378	373	370	358*	362	346*
Net cash from operating activities	(223)*	583*	(596)	834*	(1,000)*	307*	243	(444)*	(935)*	(57)*	(328)	108*
Net cash from investing activities	(328)*	(50)*	(150)	(136)*	(37)*	(58)*	(47)	(58)*	(58)*	(84)*	(22)	(64)*
Proceeds from issuing common stock	—	0*	—	—	—	(4)*	—	—	0*	0*	—	—
Net cash from financing activities	685*	(72)*	420	(110)*	462*	(203)*	(183)	562*	572*	39*	476	222*
Net change in cash	134*	461*	(326)	588*	(575)*	46*	13	60*	(421)*	(102)*	126	266*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Intellia Therapeutics	106,128	7,659	(83,113)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.